Physician profile
Faizuddin M Khaja
NPI 1043409873
$5,192.85
in general payments reported to CMS, 2019-2025
29 companies · $1,246 in 2025
The $1,246 reported for 2025 was more than what 82% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $619 · 2020: $167 · 2021: $452 · 2022: $208 · 2023: $913 · 2024: $1,589 · 2025: $1,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,747.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,315.60 | 2020-2025 | Eylea Hd, Eylea |
| Alimera Sciences, INC. | $624.56 | 2019-2024 | Yutiq, Iluvien |
| Genentech USA, INC. | $469.40 | 2019-2025 | Vabysmo |
| Johnson & Johnson Surgical Vision, INC. | $451.39 | 2019-2025 | Tecnis Iol, Veritas Vision System |
| Astellas Pharma US INC | $313.78 | 2023-2025 | Izervay |
| Apellis Pharmaceuticals, INC. | $297.05 | 2023-2025 | Syfovre |
| Abbvie INC. | $229.15 | 2022-2025 | |
| Allergan, INC. | $218.51 | 2019-2021 | |
| Harrow Eye, LLC | $149.80 | 2025 | Vevye |
| Alcon Vision LLC | $148.90 | 2023-2025 | Clareon, Argos, Centurion |
| Halozyme INC | $147.48 | 2019-2025 | Hylenex Recombinant |
| Dompe US, INC. | $111.65 | 2025 | Oxervate |
| Rxsight INC | $103.42 | 2024 | Light Adjustable Lens (Lal), Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Biogen, INC. | $100.90 | 2022-2024 | Byooviz |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $98.84 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyepoint US, INC. | $85.30 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $55.45 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $53.78 | 2025 | Purified Cortrophin Gel, Yutiq |
| Bausch & Lomb Americas INC. | $37.26 | 2022-2023 | Xipere, Retisert, Visudyne |
| Glaukos Corporation | $27.34 | 2019 | |
| Mallinckrodt Hospital Products INC. | $26.42 | 2024 | Acthar |
| Coherus Oncology, INC. | $23.97 | 2023 | |
| Sight Sciences, INC. | $22.03 | 2025 | Omni Surgical System |
| Mallinckrodt Enterprises LLC | $17.70 | 2019 | |
| Amgen INC. | $14.61 | 2024 | Tepezza |
| Shire North American Group INC | $13.36 | 2019 | |
| Ocular Therapeutix, INC. | $11.92 | 2022 | |
| Lkc Technologies, INC. | $11.82 | 2023 | |
| Spark Therapeutics, INC. | $11.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faizuddin Khaja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.